Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label dose-escalation study of intracranial SI-053 added to standard of care in adults with newly diagnosed glioblastoma
NL-OMON58928Phase 1Not yet recruiting
- Sponsor
- Double Bond Pharmaceutical
- Start
- Jan 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Temodex and temozolomide in glioblastoma (GBM), sponsored by Double Bond Pharmaceutical. Primary endpoints: Maximum tolerated dose and Dose-limiting toxicities. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
Temodextemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON58928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58928.